Abstract:Dear Editor, Erythrodermic psoriasis (EP) is an uncommon, severe variant of psoriasis characterized by widespread erythema of the skin, triggered by various factors, including pharmacological agents, infections, psychogenic stress, and alcohol. Here we report a unique case of EP triggered by B-cell chronic lymphocytic leukemia (CLL). A 60-year-old man with a 10-year history of chronic plaque psoriasis was referred for a sudden onset of erythroderma, which progressed rapidly to affect all body sites and persisted for 2 months. He also complained of fatigue, weight loss, and enlarged peripheral lymph nodes. At the initial presentation, generalized erythema with scaling was observed in more than 90% of the body surface area (Figure 1A). Skin biopsy showed features characteristic for psoriasis (Figure 1B). The infiltrating lymphocytes were predominantly CD4 positive and CD8 positive T cells, while CD20 positive B cells were scarce, excluding the leukemia skin infiltration (Figure 1C-F). Sustained elevations of peripheral white blood cells (13 040-14 270/μL, normal range 3500-9500/μL) and lymphocytes (8410-8460/μL, normal range 1100-3200/μL) were found during the past 2 months. Peripheral blood immunophenotype demonstrated monoclonal B-cell lymphocytosis with the expression of CD19, CD23, CD5, and kappa immunoglobulin light chain. A bone marrow biopsy confirmed the involvement of CLL. Therefore, EP with concurrent CLL, Binet stage B, was diagnosed. Topical steroid ointment was prescribed for psoriasis. Treatment for CLL was not initiated due to its low risk. The alleviation of his erythroderma was found to be along with a decrease in peripheral lymphocytes (Figure 1G). During follow-up, the severity of psoriatic lesions fluctuated with his lymphocyte count. The erythroderma relapsed when the lymphocyte count increased and subsided when it dropped to the normal range (Figure 1H). Oral low-dose methotrexate was applied to control the last flare-up in December, 2019. His skin disease and lymphocyte count gradually subsided and remained stable since then. EP is characterized by generalized erythema and scaling, with systemic symptoms of fever, lymphadenopathy, and weight changes. Generalized erythroderma may present suddenly or by worsening of chronic plaque psoriasis, triggered by infection, stress, alcoholism, and systemic illness (such as HIV and T-cell lymphoma). Chronic lymphocytic leukemia, a neoplasm composed of monomorphic small mature B cells, is a common leukemia in Western countries. Most patients are asymptomatic, and the diagnosis relies on routine blood analysis. Our case revealed a temporal relationship between psoriatic erythroderma and peripheral B-cell lymphocytosis caused by CLL. Similar phenomena had also been reported in patients who developed concurrent EP and B-cell lymphocytosis/leukemia. This close association suggests a pathogenic link underlying these two conditions. The pathogenesis of EP is not well understood; however, the disease may be associated with a predominant T helper 2 (Th2) phenotype. B cells are important during the Th2-type immune response and drive Th2 responses by instructing human dendritic cell maturation. Therefore, it is possible that the accumulation of circulating malignant B cells in our patient exacerbated the T cell inflammation in the skin and transformed plaque psoriasis to erythroderma via Th2 cytokines. Tumor necrosis factor-α (TNF-α), a well-known trigger for psoriasis, is another suspicious factor. TNF-α has been shown to be produced by leukemic lymphocytes in CLL patients and act as an autocrine and paracrine growth factor. The elevated autocrine TNF-α may contribute to the exacerbation of psoriasis. Therefore, antiinflammatory therapies, including TNF inhibitors, may serve as potential therapeutic options for this situation, as reported previously. This case provides new information about the triggers for EP. B-cell malignancy should be considered in patients with exacerbated psoriasis and peripheral lymphocytosis.

Erythrodermic Psoriasis Exacerbated by Bupropion

Severe Hyperhidrosis Secondary to Bupropion Use and Treatment. A case report.

Delayed allergic reaction from bupropion in a 27-year-old male with MDD: A case report and literature review

Multidimensional assessment of adverse events of bupropion: A large-scale data analysis from the FAERS database

Bupropion-Induced Dystonia: A Case Report

Clinical and electrocardiographic factors associated with adverse cardiovascular events in bupropion exposures

Clinical Presentations of Bupropion Prescription Drug Misuse

Bupropion: Does Its Efficacy Outweigh Potential Morbidity and Lethality?

Cardiovascular Collapse Requiring Veno-Arterial Extracorporeal Membrane Oxygenation and Lidocaine: A Case of Massive Bupropion Overdose

Successful Management of Severe Bupropion Toxicity with Lipid Emulsion Therapy: A Complex Case Report and Literature Review

Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion

Bupropion-disguised chest pain presenting in a middle-aged male: a case report and review of literature

Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation

Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis

Tazarotene/Betamethasone Dipropionate Cream in Patients with Plaque Psoriasis: Results of a Prospective, Multicenter, Observational Study.

Abstract 17489: Bupropion Poisoning: Extracorporeal Membrane Oxygenation as a Rescue Strategy

Exposure to Bupropion-SR vs. Placebo is associated with reductions in smoking among persons receiving methadone with no stated interest in smoking cessation

Erythrodermic Psoriasis Precipitated by B‐cell Chronic Lymphocytic Leukemia

Abstract 15659: Bupropion Overdose Requiring Veno-Arterial Extracorporeal Membrane Oxygenation

Addendum: Bupropion Safety in Pregnancy

Bupropion Increased More than Five Times the Systemic Exposure to Aripiprazole: An In Vivo Study in Wistar albino Rats